Inclusion Criteria:  Aged over 18 years and less than 75 years of age on the date of the Screening Visit; Have back and or neck pain of at least three months duration; Have an average back or neck pain score of between 5 and 9 on a 10-point visual analogue pain scale; Have failed to achieve self-reported satisfactory pain relief using over-the-counter paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs); Are willing to cease current pain medications for the duration of the study (except as allowed under rescue medication); Agree to cease any dietary or herbal supplements (e.g. St John's Wort) three to seven days prior to commencing Cybis™ 10:25, and for the duration of the study; Are willing to cease driving a car or operating heavy machinery from the day of first dosing to seven days after administration of the last dose of Cybis™ 10:25; Agree to use contraception throughout the study, and for one month after the last dose of Cybis™ 10:25 is administered (if reproductive age female) or three months after the last dose of Cybis™ 10:25 is administered (if male); Note: women of childbearing potential must have a negative blood pregnancy test prior to entry into the study. For women, adequate contraception is a double barrier method for the duration of the study and for 30 days post the last study dose. For men, barrier contraception is required for the duration of the study and for 3 months after the last study dose. Agree to adhere to the study protocol; and Are willing and able to provide written informed consent.  Exclusion Criteria:  Are pregnant or breastfeeding; Currently using marijuana or other medicinal cannabis products; History of cannabis use disorder; Current or previous allergies or allergic responses to any of the components of the study treatment (e.g., THC, CBD, MCT); Current or previous allergies or allergic responses to any of the components of the rescue medication (e.g. paracetamol, ibuprofen, aspirin, other NSAIDs); Significant cardiac disease (e.g. poorly controlled hypertension, symptomatic ischaemic heart disease, symptomatic heart failure); Chronic liver disease with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper level or normal limits; Chronic renal impairment with eGFR <30mL/min; Taking sildenafil or other PDE5 inhibitors; Being treated with known inducers/inhibitors of CYP3A4, in particular clarithromycin, rifampicin, azole antifungals, clarithromycin, antiretroviral agents, anticonvulsants (phenytoin, carbamazepine), SSRI within 30 days of study commencement; Use of such enzyme-altering agents is prohibited throughout the study. Have a major psychiatric disorder (e.g. schizophrenia, psychosis, bipolar disorder, but not anxiety or depression), by history or examination; Are currently using any illicit drug (including, but not limited to, amphetamines, cocaine); Have a history of other substance abuse disorder (as defined by DSM-5); Have active substance abuse disorder (alcohol, illicit drugs); or Other clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, or vital signs, which in the opinion of the Investigator, may put the participant at risk of adverse events; Other chronic disease (other than chronic pain) that in the opinion of the Investigator may impact the safety, efficacy and/or pharmacokinetics of the study drug; Are currently participating in, or have participated (in the last 30 days) in a drug or device clinical trial.